Alvotech Corrects Disclosure on December 2025 Insider-Related Share Transactions

Alvotech ( (ALVO) ) has issued an announcement.

On January 6, 2026, Alvotech announced that ATP Holdings ehf., a company closely associated with CEO and chairman Róbert Wessman, had reported to the Luxembourg financial regulator the acquisition of 4,812,257 Alvotech shares on December 17, 2025, and the sale of 2,110,640 shares on December 19, 2025, both at a price of SEK 44.06 per share. The disclosure, formalized in a Form 6-K filed on January 7, 2026, corrects an earlier same-day announcement that had mistakenly characterized the December 19, 2025 transaction as an acquisition rather than a sale, underscoring the company’s obligation to provide accurate reporting of insider-related dealings to both Luxembourg and U.S. market participants.

The most recent analyst rating on (ALVO) stock is a Sell with a $5.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.

Spark’s Take on ALVO Stock

According to Spark, TipRanks’ AI Analyst, ALVO is a Neutral.

Alvotech’s overall stock score is driven by financial instability, bearish technical indicators, and regulatory challenges impacting short-term outlook. While strategic investments and historical growth are positives, significant risks remain.

To see Spark’s full report on ALVO stock, click here.

More about Alvotech

Alvotech is a Luxembourg-based foreign private issuer listed in the United States, operating in the pharmaceutical sector with a focus on biosimilar medicines. The company is regulated in part through the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) and reports to U.S. investors under the Securities Exchange Act via Form 6-K and related shelf and equity compensation registration statements.

Average Trading Volume: 617,144

Technical Sentiment Signal: Sell

Current Market Cap: $1.43B

For an in-depth examination of ALVO stock, go to TipRanks’ Overview page.